Sheep VMAT-2 C-Terminus Antibody

<strong>Sheep VMAT-2 C-Terminus Antibody</strong>_x000D_ <strong>Catalog number:</strong> B2012619_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 uL_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> Sheep antibody_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Anticancer radioimmunotherapy Oncoimmunology. 2013 Sep 1;2(9):e25595._x000D_ 2: Tfayli AH, Sfeir PM, Youssef BY, Khuri FR. Locally advanced lung cancer CA Cancer J Clin. 2021 Nov;71(6):461-465._x000D_ 3: Comet B, Lartigau E. [Reirradiation of head and neck cancers] Cancer Radiother. 2010 Oct;14(6-7):416-20._x000D_ 4: Wendt TG. [Errors and hazards in oncology: radiation oncology] Laryngorhinootologie. 2013 Apr;92 Suppl 1:S199-204._x000D_ 5: Cañedo G, Solis I, González-San Segundo C, Madero L, Lassaletta A. Treatment of radiation-induced myelopathy with bevacizumab Clin Transl Oncol. 2020 Jun;22(6):957-960._x000D_ 6: Ashe KM, Chiu WL, Khalifa AM, Nicolas AN, Brown BL, De Martino RR, Alexander CP, Waggener CT, Fischer-Stenger K, Stewart JK. Vesicular monoamine transporter-1 (VMAT-1) mRNA and immunoreactive proteins in mouse brain Neuro Endocrinol Lett. 2011;32(3):253-8._x000D_ 7: Zhou X, Liu P, Wang X. Temporal Lobe Necrosis Following Radiotherapy in Nasopharyngeal Carcinoma: New Insight Into the Management Front Oncol. 2021 Jan 21;10:593487._x000D_ 8: Hiddinga BI, Surmont VF, Van Meerbeeck JP. Management of malignant pleural mesothelioma: have we made any progress? Panminerva Med. 2013 Jun;55(2):157-73._x000D_ 9: Joensuu H, Tenhunen M. Physical and biological targeting of radiotherapy Acta Oncol. 1999;38 Suppl 13:75-83._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/21592702">10: Yoshizaki T, Ito M, Murono S, Wakisaka N, Kondo S, Endo K. Current understanding and management of nasopharyngeal carcinoma Auris Nasus Larynx. 2012 Apr;39(2):137-44. </a>_x000D_ _x000D_ <strong>Products Related to Sheep VMAT-2 C-Terminus Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>